Skip to main content

Renal-Cell Carcinoma

Tolerance of Oral Targeted Agents in Patients With Advanced or Metastatic RCC With and Without Renal Impairment
Bradley Mayer, PharmD, BCOP; Emma Carroll, PharmD, BCOP; Melissa Rhoades, PharmD, BCOP; Felicia Zook, PharmD, BCOP
Read More
Reduced Starting Dose of Tyrosine Kinase Inhibitors in Patients with Metastatic Renal-Cell Carcinoma
Tia M. Stitt, PharmD; Katherine M. Saunders, PharmD, BCOP; Brooke C. Rowling, PharmD Candidate; Jennifer L. Waller, PhD; Amber B. Clemmons, PharmD, BCOP, FHOPA
Read More
Minimal Activity with Sapanisertib in Refractory Renal-Cell Carcinoma
Read More
Active Therapy Improves Survival versus BSC After Disease Progression on Nivolumab and Cabozantinib
Read More
Real-World Treatment Patterns Have Drastically Changed Over the Past 5 Years
Read More
Functional Imaging Predicts Outcomes in Patients Treated with Antiangiogenic Therapy
Read More
Development of a Prognostic Biomarker Score for Nivolumab in Relapsed/Refractory Disease
Read More
Clinical Activity of Lenvatinib with or without Everolimus in Heavily Pretreated Disease
Read More
Nivolumab Rechallenge Associated with Moderate Efficacy
Read More
Stereotactic Radiotherapy Delays Treatment Switch in Those with Oligoprogression
Read More
Page 1 of 3
Results 1 - 10 of 27